Table 2.
Stratification analysis for association between PARP1 gene genotypes and neuroblastoma susceptibility
| Variables | rs1136410 (case/control) |
AOR (95% CI)a | Pa | rs2666428 (case/control) |
AOR (95% CI)a | Pa | rs8679 (case/control) |
AOR (95% CI)a | Pa | Risk genotypes (case/control) |
AOR (95% CI)a | Pa | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AA | AG/GG | TT | TC/CC | AA | AG/GG | 0-1 | 2-3 | |||||||||
| Age, month | ||||||||||||||||
| ≤18 | 53/128 | 116/262 | 1.06 (0.72-1.57) | 0.757 | 109/244 | 60/146 | 0.92 (0.63-1.34) | 0.650 | 141/348 | 28/42 | 1.64 (0.98-2.75) | 0.061 | 43/114 | 126/276 | 1.20 (0.80-1.81) | 0.381 |
| >18 | 83/202 | 217/406 | 1.30 (0.96-1.77) | 0.087 | 196/392 | 104/216 | 0.97 (0.72-1.29) | 0.819 | 266/523 | 34/85 | 0.80 (0.52-1.23) | 0.310 | 72/167 | 228/441 | 1.21 (0.88-1.66) | 0.252 |
| Gender | ||||||||||||||||
| Female | 62/138 | 134/276 | 1.08 (0.75-1.55) | 0.681 | 126/272 | 70/142 | 1.07 (0.75-1.52) | 0.722 | 175/372 | 21/42 | 1.07 (0.61-1.86) | 0.816 | 56/119 | 140/295 | 1.01 (0.69-1.47) | 0.968 |
| Male | 74/192 | 199/392 | 1.32 (0.96-1.81) | 0.091 | 179/364 | 94/220 | 0.87 (0.64-1.17) | 0.343 | 232/499 | 41/85 | 1.03 (0.69-1.54) | 0.896 | 59/162 | 214/422 | 1.39 (0.99-1.95) | 0.060 |
| Sites of origin | ||||||||||||||||
| Adrenal gland | 52/330 | 110/668 | 1.03 (0.72-1.48) | 0.857 | 100/636 | 62/362 | 1.10 (0.78-1.56) | 0.571 | 144/871 | 18/127 | 0.86 (0.51-1.46) | 0.579 | 45/281 | 117/717 | 1.01 (0.69-1.46) | 0.972 |
| Retroperitoneal | 40/330 | 98/668 | 1.21 (0.82-1.78) | 0.351 | 89/636 | 49/362 | 0.95 (0.66-1.38) | 0.801 | 118/871 | 20/127 | 1.14 (0.68-1.90) | 0.614 | 32/281 | 106/717 | 1.30 (0.85-1.97) | 0.227 |
| Mediastinum | 28/330 | 93/668 | 1.65 (1.06-2.56) | 0.028 | 78/636 | 43/362 | 0.98 (0.66-1.45) | 0.905 | 102/871 | 19/127 | 1.32 (0.78-2.24) | 0.296 | 24/281 | 97/717 | 1.60 (1.00-2.55) | 0.050 |
| Others | 13/330 | 27/668 | 1.03 (0.53-2.02) | 0.931 | 32/636 | 8/362 | 0.44 (0.20-0.96) | 0.040 | 37/871 | 3/127 | 0.56 (0.17-1.85) | 0.343 | 12/281 | 28/717 | 0.92 (0.46-1.84) | 0.823 |
| Clinical stage | ||||||||||||||||
| I+II+4s | 68/330 | 165/668 | 1.21(0.88-1.65) | 0.241 | 150/636 | 83/362 | 0.97 (0.72-1.31) | 0.833 | 202/871 | 31/127 | 1.07 (0.70-1.63) | 0.758 | 57/281 | 176/717 | 1.22 (0.88-1.70) | 0.231 |
| III+IV | 62/330 | 154/668 | 1.21 (0.88-1.68) | 0.243 | 144/636 | 72/362 | 0.88 (0.64-1.20) | 0.402 | 190/871 | 26/127 | 0.92 (0.59-1.45) | 0.726 | 55/281 | 161/717 | 1.13 (0.81-1.58) | 0.484 |
AOR, adjusted odds ratio; CI, confidence interval.
a Adjusted for age and gender, omitting the corresponding stratify factor.